Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

Experimental neonatal chronic lung disease is marked by a redox imbalance that damages the lungs, and that damage can be ameliorated using a live biotherapeutic mixture of three Lactobacillus species.
This finding suggests utility of treatments before fecal microbial transplants to reduce recipient microbial communities. This would help donor microbial strains dominate in the recipient.
Experiments reveal that a catalytic subunit of CK2, called CK2α, is an important regulator of mouse CD8+ T cell activation, metabolic reprogramming and differentiation, both in vitro and in a mouse-infection model by the intracellular pathogen Listeria monocytogenes.
Direct reprogramming is a potential therapy for heart attack patients. In vitro, TBX20 improved contractility and mitochondrial function of reprogrammed heart muscle cells.
Diseases linked to atherosclerosis are the leading cause of death in the United States.
This novel finding will help guide successful therapeutic design and strategies for acute kidney injury and chronic kidney disease.
Knockout of TXNIP improves diabetes-associated hyperglycemia and hyperglucagonemia.
The clinically approved drug ruxolitinib suppressed a mouse model of melanoma that is resistant to immune checkpoint blockers.
Noninvasive ventilation is possible in infants at limits of viability. But unlike in slightly older preterm infants, noninvasive ventilation did not show an advantage in infants of 22 weeks-0 days to 23 weeks-6 days gestational age.
Zhang wins $11.2 million NIH PPG grant to improve heart attack recovery through growth of new heart muscle cells.
Page 1 of 44